DermTech Company Overview
About DermTech
DermTech (NASDAQ:DMTK) specializes in developing and bringing to market non-invasive genomics tests for the early detection of skin cancer and other skin diseases. Their innovative approach revolves around the analysis of skin samples collected through adhesive patches, which offer a less invasive alternative to traditional biopsy methods. This technology not only aims to improve the detection and management of skin disorders but also aspires to enhance patient care by minimizing discomfort and potential complications associated with conventional procedures. DermTech's primary objective is to transform dermatological diagnostics through its pioneering genomic analysis techniques, making early detection more accessible and less invasive for patients worldwide. Their projects focus on expanding the applications of their technology to cover a broader range of skin conditions, ultimately striving to set new standards in the field of dermatology.
Snapshot
Operations
Produtos e/ou serviços de DermTech
- The Pigmented Lesion Assay (PLA) for early detection of melanoma using non-invasive adhesive patch biopsies.
- The Non-Invasive Genomic Patch Testing Service for skin cancer detection and monitoring.
- Luminate, a gene expression test providing melanoma risk assessment and personalized genomic information.
- The Adhesive Skin Collection Kit, enabling convenient at-home sample collection for genomic analysis of skin conditions.
- Melanoma Risk Score, a tool based on genetic markers to quantify an individual's risk of developing melanoma.
- Neoplasia Risk Score, designed to assess the risk of non-melanoma skin cancers through genomic analysis.
equipe executiva do DermTech
- Mr. Bret ChristensenPresident, CEO & Director
- Mr. Kevin Sun M.B.A.CFO, Treasurer & Secretary
- Mr. Ray Akhavan Esq., J.D.General Counsel